A new study suggests that the antiviral Molnupiravir may “paradoxically” be driving COVID-19 mutations, creating variants of concern. What is going on? It is all about molnupiravir’s mode of action ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
There are currently two approved COVID-19 treatments that can be taken orally: nirmatrelvir-ritonavir (known as Paxlovid and developed by Pfizer) and Merck’s molnupiravir. They have both been shown to ...